10 active not recruiting, 9 recruiting, 1 completed. 11 Phase 2, 4 Phase 3, 3 Phase 1, 2 Early Phase 1.
Follow Volrustomig: new trials by email Literature Review of Volrustomig trials Research Report on Volrustomig
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Response-Adaptive Treatment in Untreated Locoregional HPV-Negative Head and Neck Cancer Volrustomig, Carboplatin, Paclitaxel - Head and Neck Cancer, HPV | Phase 2 | Recruiting | University of Chicago | 38 | 2025-10-07 | 2026-03-04 |
| A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC Volrustomig, Casdatifan - Advanced Clear Cell Renal Cell Carcinoma | Phase 1 | Active not recruiting | AstraZeneca | 9 | 2025-07-28 | 2026-08-03 |
| A Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (IVOLGA) Volrustomig - Locally Advanced Cervical Cancer | Phase 2 | Active not recruiting | AstraZeneca | 37 | 2025-03-31 | 2026-08-18 |
| A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer Volrustomig, FOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan), Bevacizumab - Metastatic Colorectal Cancer | Phase 2 | Active not recruiting | AstraZeneca | 82 | 2025-03-12 | 2026-10-22 |
| Volrustomig Priming Regimens Exploratory Phase II Platform Study Volrustomig, Carboplatin, Pemetrexed - Non-small Cell Lung Cancer | Phase 2 | Active not recruiting | AstraZeneca | 194 | 2024-08-27 | 2026-09-29 |
| Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors Volrustomig, Cisplatin, Carboplatin - Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy) | Phase 2 | Recruiting | AstraZeneca | 257 | 2024-08-22 | 2026-09-11 |
| PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC Rilvegostomig, Volrustomig, Sabestomig - Head and Neck Squamous Cell Carcinoma | Early Phase 1 | Completed | Presage Biosciences | 17 | 2024-05-22 | 2026-06-26 |
| A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy volrustomig - Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 3 | Recruiting | AstraZeneca | 1145 | 2023-12-14 | 2026-09-30 |
| MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma Volrustomig, Pemetrexed, Carboplatin - Unresectable Pleural Mesothelioma | Phase 3 | Active not recruiting | AstraZeneca | 863 | 2023-11-09 | 2026-10-23 |
| A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer. Volrustomig, Pembrolizumab, Carboplatin - Metastatic Non-small Cell Lung Cancer | Phase 3 | Active not recruiting | AstraZeneca | 895 | 2023-10-24 | 2026-10-09 |
| Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical) Volrustomig, Placebo - Locally Advanced Cervical Cancer | Phase 3 | Recruiting | AstraZeneca | 800 | 2023-09-22 | 2026-09-30 |
| Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer Volrustomig, Bevacizumab, Lenvatinib - Hepatocellular Carcinoma, Biliary Tract Cancer | Phase 2 | Active not recruiting | AstraZeneca | 294 | 2023-04-24 | 2026-08-24 |
| Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Rilvegostomig, Volrustomig, FOLFOX - Gastric Cancer | Phase 2 | Recruiting | AstraZeneca | 163 | 2023-01-16 | 2026-05-14 |
| Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Datopotamab deruxtecan (Dato-DXd), Capecitabine, 5-Fluorouracil - Endometrial Cancer, Gastric Cancer | Phase 2 | Recruiting | AstraZeneca | 454 | 2022-09-06 | 2026-09-23 |
| Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer Durvalumab, Oleclumab, Monalizumab - Non-small Cell Lung Cancer | Phase 2 | Recruiting | AstraZeneca | 630 | 2022-04-14 | 2026-10-21 |
| Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies Rilvegostomig, Volrustomig, Sabestomig - Solid Tumor | Early Phase 1 | Active not recruiting | Presage Biosciences | 15 | 2021-07-26 | 2026-05-22 |
| Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC T-DXd, Durvalumab, Cisplatin - Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Phase 1 | Recruiting | AstraZeneca | 304 | 2021-03-09 | 2026-04-13 |
| Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer Datopotamab deruxtecan, Durvalumab, Carboplatin - Advanced or Metastatic NSCLC | Phase 1 | Active not recruiting | AstraZeneca | 155 | 2021-02-02 | 2026-10-27 |
| WIRE - Novel Treatments in Renal Cell Cancer Olaparib, Cediranib, Volrustomig - Renal Cell Cancer | Phase 2 | Recruiting | CCTU- Cancer Theme | 134 | 2020-07-27 | 2026-09-25 |
| Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) Fluorouracil (5-FU), Capecitabine, Durvalumab - Gastric Cancer | Phase 2 | Active not recruiting | AstraZeneca | 452 | 2020-06-03 | 2026-08-28 |
Carcinoma, Non-Small-Cell Lung (5) · Head and Neck Neoplasms (3) · Squamous Cell Carcinoma of Head and Neck (3) · Stomach Neoplasms (3) · Biliary Tract Neoplasms (2) · Carcinoma, Renal Cell (2) · Colorectal Neoplasms (2) · Adenocarcinoma (1) · Carcinoma (1) · Carcinoma, Hepatocellular (1) · Diabetes Mellitus, Insulin-Dependent, 12 (1) · Endometrial Neoplasms (1) · Esophageal Neoplasms (1) · Esophageal Squamous Cell Carcinoma (1) · Kidney Neoplasms (1)
AstraZeneca (16) · Presage Biosciences (2) · CCTU- Cancer Theme (1) · University of Chicago (1)
United States (17) · South Korea (14) · Taiwan (14) · Italy (13) · Spain (13) · China (12) · Canada (10) · Japan (10) · United Kingdom (10) · France (8) · Germany (8) · Poland (8) · Turkey (Türkiye) (8) · Brazil (7) · Australia (6)
Arnaud Scherpereel, MD (1) · Brent O'Carrigan (1) · Grant D Stewart (1) · Lisa Licitra, MD (1) · Marjorie G Zauderer, MD (1) · Robert Haddad, MD (1) · Tina Cascone, MD (1)
PMID 34794412, PMID 36923556, PMID 38981998, PMID 40341124, PMID 40450142, PMID 41369900, PMID 41448488
2023 (8), 2019 (1)